<DOC>
	<DOCNO>NCT01115842</DOCNO>
	<brief_summary>Vitamin D know immune-modulator effect include suppression proinflammatory cytokine expression regulation immune cell activity . Vitamin D supplementation associate reduction pro-inflammatory cytokine patient heart failure , vitamin D deficiency associate high rate myocardial infarct . The level pro anti-inflammatory cytokine also effect outcome acute coronary event . The propose interventional study target feasibility study target assess role vitamin D anti-inflammatory mediator . The study plan randomize open label interventional trial . The study conduct 50 adult patient ( 25 interventional group , 25 control ) , internal ward `` Meir '' medical center . Patients admit acute coronary event randomize Vitamin D supplementation group control group . vitamin D group receive 4000IU per day vitamin D five day . Cytokine level measure day 1 day 5. follow continue 6 month Primary end point : Levels immune mediate cytokine ( CRP , TNF-Î± . Il-2 , IL-6 , IL-12 IL-10 ) five day intervention patient serum . Secondary endpoint : Any major cardiovascular event within follow-up period . Any death cause follow-up period Expected result : investigator expect vitamin D supplementation pro-inflammatory state acute coronary event , combine conventional therapy , result decrease level inflammatory serum bio-markers .</brief_summary>
	<brief_title>Vitamin D Inflammatory Cytokine Levels After Acute Myocardial Infraction ( MI )</brief_title>
	<detailed_description>Inclusion criterion : - Acute coronary syndrome ( define previously ) . - No advanced renal disease ( creatinine level &lt; 1.8 men 1.5 woman ) . - No know parathyroid calcium homeostasis abnormalities - Baseline Calcium level within normal limit . - No vitamin D supplementation take within 4 month current admission . - No coexist pro-inflammatory condition ( e.g . infection , active autoimmune disease ) - No coexist immune-mediator agent ( e.g . corticosteroid , anti-TNF biological agent ) . - No participation interventional study . - Signing informed consent form . Exclusion criterion : - Advanced renal failure - Abnormal serum calcium level upon admission - Primary parathyroid calcium homeostasis abnormality . - Coexisting pro-inflammatory condition ( e.g . infection , active autoimmune disease ) - Coexisting immune-mediator agent ( e.g . corticosteroid , anti-TNF biological agent ) - Participation interventional study . - Inability refusal sign inform consent .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Acute coronary syndrome ( define previously ) . No advanced renal disease ( creatinine level &lt; 1.8 men 1.5 woman ) . No known parathyroid calcium homeostasis abnormality Baseline Calcium level within normal limit . No vitamin D supplementation take within 4 month current admission . No coexist proinflammatory condition ( e.g . infection , active autoimmune disease ) No coexist immunemediatory agent ( e.g . corticosteroid , antiTNF biological agent ) . No participation interventional study . Signing informed consent form . Advanced renal failure Abnormal serum calcium level upon admission Primary parathyroid calcium homeostasis abnormality . Coexisting proinflammatory condition ( e.g . infection , active autoimmune disease ) Coexisting immunemediator agent ( e.g . corticosteroid , antiTNF biological agent ) Participation interventional study . Inability refusal sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>inflammatory cytokine</keyword>
</DOC>